273 related articles for article (PubMed ID: 8443808)
41. Phase I trial of interleukin-2 plus gamma-interferon.
Margolin KA; Doroshow JH; Akman SA; Leong LA; Morgan RJ; Raschko J; Somlo G; Mills B; Goldberg D; Sniecinski I
J Immunother (1991); 1992 Jan; 11(1):50-5. PubMed ID: 1734948
[TBL] [Abstract][Full Text] [Related]
42. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma.
Pavone L; Fanti G; Bongiovanni C; Goldoni M; Alberici F; Bonomini S; Cristinelli L; Buzio C
Med Oncol; 2009; 26(1):38-44. PubMed ID: 18516705
[TBL] [Abstract][Full Text] [Related]
43. Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2.
Kolitz JE; Welte K; Wong GY; Holloway K; Merluzzi VJ; Engert A; Bradley EC; Konrad M; Polivka A; Gabrilove JL
J Biol Response Mod; 1987 Aug; 6(4):412-29. PubMed ID: 3498011
[TBL] [Abstract][Full Text] [Related]
44. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
Sosman JA; Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; O'Boyle K; Fisher RI; Boldt DH; Doroshow J
J Clin Oncol; 1993 Aug; 11(8):1496-505. PubMed ID: 8336188
[TBL] [Abstract][Full Text] [Related]
45. Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer.
Jansen RL; Slingerland R; Goey SH; Franks CR; Bolhuis RL; Stoter G
J Immunother (1991); 1992 Jul; 12(1):70-3. PubMed ID: 1322167
[TBL] [Abstract][Full Text] [Related]
46. A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer.
Redman BG; Flaherty L; Chou TH; al-Katib A; Kraut M; Martino S; Chen B; Kaplan J; Valdivieso M
J Clin Oncol; 1990 Jul; 8(7):1269-76. PubMed ID: 2113571
[TBL] [Abstract][Full Text] [Related]
47. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
48. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.
Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP
J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261
[TBL] [Abstract][Full Text] [Related]
49. Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.
Goldstein D; Sosman JA; Hank JA; Weil-Hillman G; Moore KH; Borchert A; Bechhofer R; Storer B; Kohler PC; Levitt D
Cancer Res; 1989 Dec; 49(23):6832-9. PubMed ID: 2819723
[TBL] [Abstract][Full Text] [Related]
50. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
51. Phase I trial of human lymphoblastoid interferon with whole body hyperthermia in advanced cancer.
Robins HI; Sielaff KM; Storer B; Hawkins MJ; Borden EC
Cancer Res; 1989 Mar; 49(6):1609-15. PubMed ID: 2647291
[TBL] [Abstract][Full Text] [Related]
52. Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.
Eisenbeis CF; Lesinski GB; Anghelina M; Parihar R; Valentino D; Liu J; Nadella P; Sundaram P; Young DC; Sznol M; Walker MJ; Carson WE
J Clin Oncol; 2005 Dec; 23(34):8835-44. PubMed ID: 16314644
[TBL] [Abstract][Full Text] [Related]
53. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.
Ernstoff MS; Gooding W; Nair S; Bahnson RR; Miketic LM; Banner B; Day R; Whiteside T; Titus-Ernstoff L; Kirkwood JM
Cancer Res; 1992 Feb; 52(4):851-6. PubMed ID: 1737346
[TBL] [Abstract][Full Text] [Related]
54. A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.
Jayson GC; Middleton M; Lee SM; Ashcroft L; Thatcher N
Br J Cancer; 1998 Aug; 78(3):366-9. PubMed ID: 9703284
[TBL] [Abstract][Full Text] [Related]
55. Phase 1 clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion.
Kohler PC; Hank JA; Moore KH; Storer B; Bechhofer R; Hong R; Sondel PM
Cancer Invest; 1989; 7(3):213-23. PubMed ID: 2790538
[TBL] [Abstract][Full Text] [Related]
56. A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2b.
Sznol M; Mier JW; Sparano J; Gaynor ER; Weiss GR; Margolin KA; Bar MH; Hawkins MJ; Atkins MB; Dutcher JP
J Biol Response Mod; 1990 Dec; 9(6):529-37. PubMed ID: 2074439
[TBL] [Abstract][Full Text] [Related]
57. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.
Rosenberg SA; Lotze MT; Yang JC; Aebersold PM; Linehan WM; Seipp CA; White DE
Ann Surg; 1989 Oct; 210(4):474-84; discussion 484-5. PubMed ID: 2679456
[TBL] [Abstract][Full Text] [Related]
58. A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma.
Witte RS; Leong T; Ernstoff MS; Krigel RL; Oken MM; Harris J; Tormey DC; Trump DL
Invest New Drugs; 1995; 13(3):241-7. PubMed ID: 8729953
[TBL] [Abstract][Full Text] [Related]
59. Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.
Farace F; Mathiot C; Brandely M; Tursz T; Dorval T; Pouillart P; Triebel F; Hercend T; Fridman WH
Clin Exp Immunol; 1990 Nov; 82(2):194-9. PubMed ID: 2122928
[TBL] [Abstract][Full Text] [Related]
60. Phase I trial of combinations of recombinant interferons beta(ser) and gamma in patients with advanced malignancy.
Schiller JH; Storer B; Willson JK; Borden EC
Cancer Treat Rep; 1987 Oct; 71(10):945-52. PubMed ID: 3115570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
